CSL’s end-2027 U.S. platform rollout commitment lifts Haemonetics
CSL’s end-2027 U.S. platform rollout commitment lifts Haemonetics 9% in pre-market trading
- Reuters reported at 3:50 ET CSL will complete rollout by end-2027
- CSL plans Haemonetics’ latest-generation plasmapheresis platform across its U.S. collection network
- This materially upgrades August’s deal, which covered only an unspecified center portion
- August 18 filing had no minimum purchases or determined implementation timetable
- CSL also arranged with incumbent Terumo to support an orderly equipment transition
- Broader deployment implies substantial recurring disposable demand alongside NexSys device installations
- The 9.13% gap is roughly 3.6 times Haemonetics’ normal daily range
- Timing matches catalyst: announcement preceded the 6:30 ET move by under three hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.